Cargando…
Post-stroke inflammation and the potential efficacy of novel stem cell therapies: focus on amnion epithelial cells
Ischemic stroke is a debilitating disease for which there are currently no effective treatments besides the clot-buster, tissue plasminogen activator (t-PA), which is administered to less than 10% of patients due to a limited (4.5 h) time window of efficacy. Thus, there is an urgent need for novel t...
Autores principales: | Broughton, Brad R. S., Lim, Rebecca, Arumugam, Thiruma V., Drummond, Grant R., Wallace, Euan M., Sobey, Christopher G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547279/ https://www.ncbi.nlm.nih.gov/pubmed/23335880 http://dx.doi.org/10.3389/fncel.2012.00066 |
Ejemplares similares
-
Amnion epithelial cells – a novel therapy for ischemic stroke?
por: Evans, Megan A., et al.
Publicado: (2018) -
Phase 1 Trial of Amnion Cell Therapy for Ischemic Stroke
por: Phan, Thanh G., et al.
Publicado: (2018) -
Protection against brain injury after ischemic stroke by intravenous human amnion epithelial cells in combination with tissue plasminogen activator
por: Barreto-Arce, Liz J., et al.
Publicado: (2023) -
The effect of human amnion epithelial cells on lung development and inflammation in preterm lambs exposed to antenatal inflammation
por: Papagianis, Paris Clarice, et al.
Publicado: (2021) -
Phase I trial outcome of amnion cell therapy in patients with ischemic stroke (I-ACT)
por: Phan, Thanh G., et al.
Publicado: (2023)